Why Tarsus Pharmaceuticals, Inc.’s (TARS) Stock Is Up 5.23%
As of Wednesday, September 02, Tarsus Pharmaceuticals, Inc.’s TARS share price has surged by 5.23%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. TARS
$74.12
-0.28
-0.38%
October 13, 2026 1:01:22 PM
EST
Volume: 295,191
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Commentary & Analysis
Why Tarsus Pharmaceuticals, Inc.’s (TARS) Stock Is Up 5.01%
As of Thursday, August 06, Tarsus Pharmaceuticals, Inc.’s TARS share price has surged by 5.01%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
What You Need to Know About Tarsus Pharmaceuticals, Inc.'s Q3 Earnings
Tarsus Pharmaceuticals, Inc.'s fiscal Q3 earnings report was released on Thursday, August 06. Let's dive in to see if (TARS) missed or beat analyst's expectations.Michael Rose
Is Tarsus Pharmaceuticals, Inc. (TARS) Overvalued?
We dive into why Tarsus Pharmaceuticals, Inc. (TARS) could be considered overvalued on 2026-08-04, based on AAII’s Value Score and Grade.Jenna Brashear
Why Tarsus Pharmaceuticals, Inc.’s (TARS) Stock Is Up 5.42%
As of Monday, August 03, Tarsus Pharmaceuticals, Inc.’s TARS share price has surged by 5.42%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | TARS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,264.9 | $511.9 | 61% |
|
| Shares Out (Mil) | 43.4 | 42.8 | 44% |
|
| Institutional Ownership | 96.7% | 82.8% | 71% |
|
| Float (Mil) | 32.7 | 44.4 | 38% |
|
| Beta | 0.54 | 0.70 | 31% |
|
| Avg Daily Volume (000s) | 852 | 372 | 67% |
|
| Price Change (52-week) |
5.7% | 59.4% | 58% |
|
| Growth | TARS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (19.9%) | (2.0%) | 20% |
|
| EPS (5yr) | 18.1% | 15.0% | 65 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (34.6%) | (15.1%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 2 | |
| Current EPS | ($1.767) | ($5.770) | ($0.360) | |
| Month Ago EPS | ($1.537) | ($2.097) | $2.416 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($1.835) | ($2.250) | $1.660 | |
| Year/Year Chg | 312.9% | 262.9% | (392.5%) | |
| Financials | TARS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $606 | $416 | 43% |
|
| Net Income (TTM) (Mil) | ($47) | ($11) | 17% |
|
| EPS (TTM) | ($1.082) | ($0.700) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | $74 | ($7) | 49% |
|
| Net Cash Flow (TTM) (Mil) | $107 | $5 | 78% |
|
| Long-Term Debt (Q1) (Mil) | $89 | $6 | 43% |
|
| Enterprise Value (Q1) (Mil) | $3,038 | $494 | 55% |
|
| Valuation | TARS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.29 | 2.24 | 90% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TARS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 82.7% | 69.4% | 90% |
|
| Net Margin | (7.7%) | 3.2% | 23% |
|
| ROA | (8.4%) | (22.2%) | 27% |
|
| ROE | (13.7%) | (21.4%) | 26% |
|
| Liabilities to Assets | 43.3% | 32.8% | 34% |
|
| F-Score | 6 | 3 | 67% |
|
Tarsus Pharmaceuticals, Inc. did not pass any screens on 10/12/2026.
